

Raffaele Addeo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2011093/publications.pdf>

Version: 2024-02-01

77
papers

2,414
citations

218677

26
h-index

214800

47
g-index

83
all docs

83
docs citations

83
times ranked

4033
citing authors

#	ARTICLE	IF	CITATIONS
1	Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem. <i>Cancers</i> , 2022, 14, 1716.	3.7	12
2	Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 102934.	1.3	0
3	Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature – A New Goal for Early Diagnosis and Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2019.	2.4	5
4	Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 901-903.	3.2	1
5	Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. <i>High-Throughput</i> , 2020, 9, 4.	4.4	1
6	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. <i>Chemotherapy</i> , 2019, 64, 48-56.	1.6	5
7	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. <i>CNS Oncology</i> , 2019, 8, CNS32.	3.0	5
8	Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. <i>Oncology Letters</i> , 2019, 18, 3873-3879.	1.8	15
9	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , 2019, 9, 1102.	2.8	15
10	CheckMate 141 trial: all that glitters is not gold. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 169-171.	3.1	11
11	Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 56-62.	0.5	5
12	Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. <i>Oncology</i> , 2018, 95, 353-359.	1.9	6
13	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). <i>Journal of Breast Oncology</i> , 2018, 11, 10784314.	1.0	1
14	Adenoid cystic carcinoma of the larynx in a 70-year-old patient: A case report. <i>Oncology Letters</i> , 2018, 16, 2783-2788.	1.8	8
15	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. <i>Future Oncology</i> , 2017, 13, 415-423.	2.4	18
16	A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 199-201.	2.4	21
17	Locally advanced paranasal sinus carcinoma: A study of 30 patients. <i>Oncology Letters</i> , 2017, 13, 1338-1342.	1.8	8
18	Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. <i>Molecular and Clinical Oncology</i> , 2016, 4, 467-471.	1.0	15

#	ARTICLE	IF	CITATIONS
19	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapson: from rash mitigation to the increase in anti-tumor activity. <i>Current Medical Research and Opinion</i> , 2016, 32, 1839-1848.	1.9	16
20	Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1075-1078.	3.1	13
21	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. <i>Future Oncology</i> , 2016, 12, 373-387.	2.4	43
22	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?. <i>World Journal of Gastroenterology</i> , 2016, 22, 6114.	3.3	27
23	Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. <i>Scientific Reports</i> , 2015, 5, 18670.	3.3	95
24	MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e233.	5.1	122
25	Acceptance and Adherence of Oral Endocrine Therapy in Women with Metastatic Breast Cancer: Exacampania Group Study. <i>Breast Journal</i> , 2015, 21, 326-328.	1.0	7
26	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
27	Squamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer. <i>Oncology Letters</i> , 2014, 8, 235-237.	1.8	6
28	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	4.4	32
29	ASCO 2013: bevacizumab and glioblastoma â€“ a marriage dissolution?. <i>Current Medical Research and Opinion</i> , 2014, 30, 1871-1873.	1.9	4
30	Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?. <i>Expert Review of Hematology</i> , 2014, 7, 517-519.	2.2	1
31	Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. <i>Future Oncology</i> , 2014, 10, 69-78.	2.4	0
32	The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy. <i>Oral Oncology</i> , 2014, 50, e1-e2.	1.5	3
33	Erlotinib: early clinical development in brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1027-1037.	4.1	17
34	Interleukin-2 and Lanreotide in the Treatment of Medullary Thyroid Cancer: In Vitro and In Vivo Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1567-E1574.	3.6	14
35	Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 729-740.	2.4	15
36	Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. <i>Supportive Care in Cancer</i> , 2013, 21, 1313-1319.	2.2	57

#	ARTICLE	IF	CITATIONS
37	The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. <i>Expert Review of Hematology</i> , 2013, 6, 587-597.	2.2	52
38	Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series. <i>Oncology</i> , 2013, 84, 265-272.	1.9	27
39	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 469-475.	3.4	82
40	Humerus Metastasis From Cholangiocarcinoma: A Case Report. <i>Gastroenterology Research</i> , 2013, 6, 39-41.	1.3	6
41	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1283-1288.	2.4	8
42	Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 603-609.	2.3	34
43	Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 881-895.	4.1	13
44	The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 139-142.	2.4	11
45	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. <i>Oncology Reports</i> , 2011, 25, 1545-8.	2.6	4
46	Receptor Activator of NF- κ B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e19234.	2.5	157
47	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 417-424.	2.9	60
48	Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , 2011, 12, 112-118.	3.4	37
49	Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1137-1143.	2.3	26
50	Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 837-844.	2.3	73
51	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Oncologist</i> , 2010, 15, 85-92.	3.7	162
52	Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 499-505.	2.4	20
53	Latest developments in targeted therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1635-1646.	2.4	8
54	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. <i>Journal of Clinical Oncology</i> , 2010, 28, 543-548.	1.6	142

#	ARTICLE	IF	CITATIONS
55	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , 2010, 9, 685-693.	3.4	34
56	Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 301-306.	2.4	84
57	Zoledronic acid: an unending tale for an antiresorptive agent. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 141-154.	1.8	50
58	MUC2 a new key for pancreas cancer prognosis. <i>Cancer Biology and Therapy</i> , 2009, 8, 1000-1001.	3.4	1
59	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 945-949.	3.1	15
60	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 863-866.	2.3	9
61	High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 39.	8.6	6
62	Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 7.	8.6	8
63	Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality. <i>Expert Review of Hematology</i> , 2009, 2, 513-515.	2.2	6
64	Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65 years of age. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 285-292.	2.3	39
65	Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. <i>Supportive Care in Cancer</i> , 2008, 16, 209-214.	2.2	18
66	Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. <i>Cancer</i> , 2008, 113, 2524-2531.	4.1	88
67	Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors. <i>Oncology Reports</i> , 2007, , .	2.6	8
68	Atypical Cutaneous Lymphoid Hyperplasia Induced by Chemotherapy in a Patient with Advanced Colon Carcinoma. <i>Clinical Colorectal Cancer</i> , 2007, 6, 728-730.	2.3	4
69	Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. <i>BMC Cancer</i> , 2007, 7, 18.	2.6	72
70	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 34-39.	2.3	66
71	Atrial fibrillation following chemotherapy for stage III diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). <i>Annals of Hematology</i> , 2005, 84, 192-193.	1.8	18
72	Conditions Suggesting Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3844-3846.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Estrogens and Progesterone Promote Persistent CCND1 Gene Activation during G1 by Inducing Transcriptional Derepression via c-Jun/c-Fos/Estrogen Receptor (Progesterone Receptor) Complex Assembly to a Distal Regulatory Element and Recruitment of Cyclin D1 to Its Own Gene Promoter. <i>Molecular and Cellular Biology</i> , 2004, 24, 7260-7274.	2.3	154
74	Glucocorticoids induce G1 Arrest of Lymphoblastic Cells through Retinoblastoma Protein Rb1 Dephosphorylation in Childhood Acute Lymphoblastic Leukemia In Vivo. <i>Cancer Biology and Therapy</i> , 2004, 3, 470-476.	3.4	11
75	The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. <i>Molecular and Cellular Endocrinology</i> , 2000, 165, 199-209.	3.2	21
76	Estrogen Induces Early and Timed Activation of Cyclin-Dependent Kinases 4, 5, and 6 and Increases Cyclin Messenger Ribonucleic Acid Expression in Rat Uterus. <i>Endocrinology</i> , 1997, 138, 978-984.	2.8	78
77	Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients. <i>Oncology Reports</i> , 0, , .	2.6	1